NF-κB dysregulation in multiple myeloma.

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Nuclear factor-kappa B (NF-κB) is a transcription factor family implicated in various cellular processes.
• Dysregulation of NF-κB signaling is increasingly recognized in hematologic malignancies, particularly multiple myeloma.
• The tumor microenvironment plays a significant role in supporting cancer cell survival and proliferation.

Purpose of the Study:

• To review the multifaceted roles of the NF-κB transcription factor system in multiple myeloma.
• To explore the involvement of NF-κB in both myeloma cells and the bone marrow microenvironment.
• To discuss the therapeutic implications of targeting NF-κB in multiple myeloma.

Main Methods:

• Literature review of scientific articles and clinical studies.
• Analysis of genomic data related to NF-κB pathway alterations in multiple myeloma patients.
• Examination of preclinical and clinical data on proteasome inhibitors targeting NF-κB.

Main Results:

• NF-κB signaling is critical for the survival and proliferation of multiple myeloma cells.
• Genomic alterations affecting NF-κB pathway components are common in multiple myeloma.
• The tumor microenvironment actively modulates NF-κB activity to support myeloma growth.
• Proteasome inhibitors, by targeting NF-κB, have shown significant efficacy in multiple myeloma treatment.

Conclusions:

• The NF-κB pathway is a key driver in multiple myeloma pathogenesis.
• Targeting NF-κB represents a validated and promising therapeutic strategy.
• Further research into NF-κB regulation and targeted therapies holds potential for improved myeloma management.